Videos

Academic clinicians have an incumbent role to improve access to novel cellular therapies, according to Marco Davila, MD, PhD.

Following the presentation of the real-world sequencing analysis, the faculty discuss how these findings align with their own clinical experience treating relapsed/refractory multiple myeloma (R/R MM).

Dr. Mansi Shah presents a multinational real-world analysis evaluating how BCMA-directed CAR-T cell therapies and BCMA bispecific antibodies are being used in routine clinical practice for patients with relapsed/refractory multiple myeloma (R/R MM).

Additional work is needed on a “significant population that develops lung cancer without a tobacco history,” according to Edward S. Kim, MD, MBA.

Patrick Borgen, MD built Brooklyn's breast cancer program from 47 patients to 8000. Now he and Joshua Feinberg, MD discuss what surgery looks like next.

In the concluding scientific discussion, Dr. Binod Dhakal, Dr. Carol Ann Huff, and Dr. Prerna Mewawalla reflect on how emerging clinical evidence is shaping the future role of BCMA-directed therapies in relapsed/refractory multiple myeloma (RRMM).

In the second case-based discussion, Dr. Binod Dhakal and Dr. Prerna Mewawalla examine treatment considerations for an older patient with relapsed/refractory multiple myeloma (RRMM), multiple comorbidities, prior anti-CD38 exposure, and limited suitability for CAR T-cell therapy.

The faculty open the Between the Lines discussion by framing why advanced biliary tract cancer (BTC) remains a difficult-to-treat malignancy with rising incidence.

Joshua Richter, MD, and Marco Davila, MD, PhD, focused on real-world CAR T-cell therapy outcomes in multiple myeloma.

Kim Stravers, an end-of-life doula and educator, outlined how training and certification standards vary across end-of-life doula organizations.

Goutham Vemana, MD, discussed navigating regional access logistics, insurance coverage, and patient assistance programs to deliver intravesical gemcitabine in NMIBC.

Joshua Richter, MD, and Marco Davila, MD, PhD, discussed what are some optimal candidates for CAR T-cell therapy in multiple myeloma.

Goutham Vemana, MD, explained how the intravesical system provides continuous treatment exposure, deeper bladder penetration, and zero systemic absorption.

Joshua Richter, MD, and Marco Davila, MD, PhD, weighed in on sequencing CAR T-cell therapy and bispecifics in multiple myeloma.

Kim Stravers, an end-of-life doula, discussed how she helps patients assert autonomy over end-of-life medical decisions, including pain management preferences.

Jun Gong, MD, presents the EMERALD-1 trial for Team Chicago Hot Dog, reviewing the phase 3, randomized, double-blind study of transarterial chemoembolization (TACE) with durvalumab, with or without bevacizumab, in unresectable hepatocellular carcinoma (HCC) amenable to embolization.

The panel discusses whether the SIERRA safety data support using the STRIDE regimen, tremelimumab plus durvalumab, in patients typically excluded from frontline hepatocellular carcinoma (HCC) trials.

Joshua Richter, MD, and Marco Davila, MD, PhD, weighed in on the optimal timing of CAR T-cell therapy for multiple myeloma.

Kim Stravers, an end-of-life doula, defined the role as a non-medical companion offering emotional and relational support to patients and their families.

Mamta Parikh, MD, MS, outlined strategies to overcome payer coverage friction and optimize ctDNA testing windows after cystectomy.

A multidisciplinary panel broke down ILC's distinct biology, imaging challenges, and emerging trial data, including OFSET and SUMMIT.

Adam D. Cohen, MD, said that more data are necessary to help determine how cevostamab can be sequenced with other T-cell–directed therapies.

Mamta Parikh, MD, MS, contextualized recent NCCN updates on ctDNA MRD testing after radical cystectomy in muscle-invasive bladder cancer.

Following the presentation of the CARTITUDE-4 trial, the faculty discuss how the study findings may influence treatment strategies for relapsed/refractory multiple myeloma (R/R MM).

Dr. Cesar Rodriguez presents findings from the phase 3 CARTITUDE-4 trial, which compared ciltacabtagene autoleucel (cilta-cel) with standard-of-care regimens in patients with relapsed/refractory multiple myeloma (R/R MM) who were refractory to lenalidomide after one to three prior lines of therapy.

Adam D. Cohen, MD, says patients with deep responses to cevostamab could stop therapy and stay in remission for years.

Ramy Sedhom, MD, blind-ranks landmark geriatric oncology and palliative care trials, picks his oncology Hall of Fame, and shares career advice on this episode of Double Blind.

Dr. Lipsky presents a second case of a 72-year-old man with symptomatic CLL requiring therapy.

Ajay K. Nooka, MD, MPH, FACP, says multiple myeloma treatment is entering an immunotherapy deluge, with more data on bispecifics ahead.

Kay Yoon-Flannery, DO, spoke about how offering robotic mastectomy locally at AtlantiCare improved patient access.